Jacobs Levy Equity Management Inc. Has $757,000 Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Jacobs Levy Equity Management Inc. lessened its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 49.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 742,462 shares of the biopharmaceutical company's stock after selling 729,255 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.36% of Sangamo Therapeutics worth $757,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of SGMO. E Fund Management Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $25,000. JPMorgan Chase & Co. lifted its position in shares of Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 21,793 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 25,000 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $28,000. Finally, Shelton Wealth Management LLC bought a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $29,000. Institutional investors own 56.93% of the company's stock.

Analyst Upgrades and Downgrades

SGMO has been the subject of several research analyst reports. Wall Street Zen initiated coverage on Sangamo Therapeutics in a research report on Thursday. They issued a "hold" rating for the company. Truist Financial cut their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Barclays cut their price objective on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Sangamo Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $4.50.

Sangamo Therapeutics Price Performance

Shares of SGMO stock traded down $0.02 on Friday, reaching $0.47. 2,505,854 shares of the stock were exchanged, compared to its average volume of 8,743,457. The stock has a market cap of $110.36 million, a PE ratio of -0.63 and a beta of 1.46. Sangamo Therapeutics, Inc. has a one year low of $0.30 and a one year high of $3.18. The stock has a 50 day moving average price of $0.69 and a 200 day moving average price of $1.27.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The firm had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. On average, research analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.